This segment focuses on the research and development of novel cell-based immunotherapies derived from induced pluripotent stem cells (iPSCs). Fate Therapeutics leverages its proprietary iPSC platform to engineer off-the-shelf NK-cell and T-cell therapies targeting various cancers and immune disorders. Key activities include preclinical studies, clinical trials, and process development for scalable manufacturing. The company's approach aims to overcome limitations of traditional autologous cell therapies by providing readily available, standardized products. This segment addresses unmet needs in oncology and immunology, offering potential for improved patient outcomes and broader accessibility to advanced therapies. Future opportunities include expanding the pipeline with novel cell types and therapeutic modalities, as well as strategic partnerships for clinical development and commercialization.

This segment is dedicated to the development of Natural Killer (NK) cell-based immunotherapies for the treatment of cancer. Fate Therapeutics engineers iPSC-derived NK cells to enhance their cytotoxic activity and target specificity against tumor cells. Research and development efforts include optimizing NK cell expansion, activation, and persistence in the tumor microenvironment. The company's NK-cell programs address a range of hematologic malignancies and solid tumors, with a focus on improving patient outcomes through off-the-shelf cell therapies. This segment leverages genetic engineering and cell reprogramming technologies to create potent and readily available NK-cell products. Future opportunities include combination therapies with other immunomodulatory agents and expansion into new cancer indications.